| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2016-02-16 | Apeiron Biologics (Austria) Columbia University (USA - NY) | cellular immunotherapies targeting the inhibition of Cbl-b in T cells | licensing |
Cancer - Oncology | Licensing agreement | |
| 2016-02-16 | Merck KGaA (Germany) Weizmann Institute (Israel) | collaboration R&D |
Cancer - Oncology | Collaboration agreement | ||
| 2016-02-16 | Bind Therapeutics (USA - MA) Synergy Pharmaceuticals (USA - NY) | Accurins® incorporating uroguanylin analogs | gastrointestinal cancers | R&D |
Cancer - Oncology | R&D agreement |
| 2016-02-15 | Charles River Laboratories (USA - MA) Eisai (Japan) | neurological diseases, malaria | collaboration R&D |
Technology - Services - Neurological diseases - Parasitic diseases | Collaboration agreement | |
| 2016-02-15 | Philogen (Italy) Abbvie (USA - IL) | armed antibody products | R&D collaboration |
Collaboration agreement | ||
| 2016-02-12 | Sandoz (Switzerland) Pfizer (USA - NY) | PF-06438179 (biosimilar version of Remicade® (infliximab)) | rheumatoid arthritis, psoriasis | product acquisition | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases - Dermatological diseases | Product acquisition |
| 2016-02-11 | Celgene (USA - NJ) | nomination |
Nomination | |||
| 2016-02-11 | Aegerion Pharmaceuticals (USA - MA) | restructuring |
Rare diseases - Genetic diseases - Metabolic diseases | Restructuring | ||
| 2016-02-10 | European Generic Medicines Association (EGA) | nomination |
Nomination | |||
| 2016-02-09 | Pharming (The Netherlands) Cytobioteck (Colombia) | Ruconest® (conestat alfa) | hereditary angioedema (HAE) | distribution |
Rare diseases - Genetic diseases - Hematological diseases | Distribution agreement |
| 2016-02-09 | Amicus Therapeutics (USA - NJ) | nomination |
Rare diseases - Genetic diseases | Nomination | ||
| 2016-02-09 | Immunovia (Sweden) Mount Sinai Health System (USA - NY) | IMMray™ PanCan-d (blood based test for early detection of pancreatic cancer) | pancreatic cancer | collaboration |
Cancer - Oncology - Diagnostic | Collaboration agreement |
| 2016-02-08 | GSK (UK) Valneva (France) | EB66® cell line for the development of EB66®-based Influenza vaccines | influenza | R&D |
Infectious diseases | R&D agreement |
| 2016-02-08 | Redhill Biopharma (Israel) Fraunhofer Institute for Cell Therapy and Immunology (IZI) (Germany) | RP101 | R&D |
Cancer - Oncology | R&D agreement | |
| 2016-02-08 | Intarcia Therapeutics (USA - CA) | nomination |
Metabolic diseases | Nomination | ||
| 2016-02-08 | Intarcia Therapeutics (USA - CA) | nomination |
Metabolic diseases | Nomination | ||
| 2016-02-08 | Global Blood Therapeutics (USA - CA) | nomination |
Rare diseases - Genetic diseases - Hematological diseases | Nomination | ||
| 2016-02-05 | Sanofi (France) | nomination |
Nomination | |||
| 2016-02-04 | Blueprint Medicines (USA - MA) | nomination |
Nomination | |||
| 2016-02-04 | Indivumed (Germany) The University of Rochester Medical Center (USA - NY) | tissue bank for cancer research | Cancer | R&D collaboration |
Cancer - Oncology | Collaboration agreement |
